Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?()

Benzer Materyaller

• Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
  Yazar:: Crusoe, Edvan de Queiroz, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
  Yazar:: Morgan, Gareth J., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
  Yazar:: Ludwig, Heinz, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  Yazar:: Crusoe, Edvan De Queiroz, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
  Yazar:: de Mello, Renan Bernardes, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)